

Dear Editors and Reviewers:

Thank you for your letter and for the reviewers' comments concerning our manuscript entitled "**Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Low-dose Rituximab: A Single-Center Experience**" (Submission ID 79139). Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval.

[Revised portion are marked in BLUE in the manuscript.](#)

Here below is our description on revision according to the reviewers' comments:

**Reviewer 1:**

**Comments:** In this study, the authors conducted a retrospective study on nine patients with refractory phospholipase A2 receptor-associated MN to explore the efficacy and safety of a new low-dose RTX regimen. The authors found that the titers of anti-PLA2R decreased after administering low-dose RTX, and four patients had a normal anti-PLA2R titer at six months. The level of CD19+ B cells decreased to 0 at three months, and the count of CD19+ B cells lasted to 0 until six months of follow-up. The results are interesting and well discussed. The reviewer recommends to accept this manuscript after a minor editing. Thank you.

**Response:** We appreciate for Editors and Reviewers' warm work earnestly, and hope that the correction will meet with approval.

**Reviewer 2:**

**Comment 1:** The abstract should be re-written as background, aim, methods, results, and conclusion.

**Response:** We have re-written the abstract as background, aim, methods, results, and conclusion.

**Comment 2:** Some minor language polishing should be corrected.

**Response:** We have carefully checked the manuscript, corrected the grammar mistakes and unclear description.

**Comment 3:** Limit of the study should be discussed.

**Response:** We have discussed the limit of our study in at the end of the “**discussion**”, and the revised portion is marked in red.

**Comment 4:** A conclusion section should be added to the main text.

**Response:** We have added the part of “**conclusion**” in the manuscript.

**Comment 5:** The references list should be edited and updated.

**Response:** The format of the references has been modified following the requirements of the journal.

Once again, thank you very much for your comments and suggestions.

Thank you and best regards.

Yours sincerely,

Ren-huan Yu